NCT04099966View on ClinicalTrials.gov

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Acute LeukemiaSevere Aplastic AnemiaNon-hodgkin LymphomaHodgkin LymphomaKostmannDiamond Blackfan AnemiaAmegakaryocytic ThrombocytopeniaSickle Cell DiseaseBeta-Thalassemia
Interventions
DRUG

alpha beta depletion

donor cells will be collected and subsequently undergo α/β CD3+/CD19+ cell depletion.

Trial Locations (1)

10595

RECRUITING

New York Medical College, Valhalla

All Listed Sponsors
lead

Mitchell Cairo

OTHER